Schwab stock slips as Fed minutes put rate outlook back in focus

Schwab stock slips as Fed minutes put rate outlook back in focus

NEW YORK, December 30, 2025, 14:00 ET — Regular session

The Charles Schwab Corp’s shares were down 0.6% at $100.69 in afternoon trading on Tuesday, after opening at $101.58 and trading between $100.34 and $101.60. The broader market was little changed, while rivals Interactive Brokers and Robinhood also traded lower.

The move matters because Schwab earns a large share of its revenue from client cash, making the stock sensitive to shifts in interest-rate expectations. That sensitivity can show up quickly on quiet days, when small changes in rate bets have an outsized impact on financial stocks.

Investors are also looking to Federal Reserve minutes due later Tuesday for clues on the policy path after the central bank’s Dec. 9-10 meeting, as U.S. stocks trade in holiday-thin conditions near the end of the year, according to Reuters. Reuters

“The meeting minutes will likely show a range of opinions about the outlook for Fed policy,” said Cooper Howard, director of fixed income research and strategy at the Schwab Center for Financial Research. Howard said he still expects the Fed to move slowly and sees “one or two” additional cuts next year. Schwab Brokerage

For Schwab, lower rates can squeeze net interest income — the gap between what it earns on investments funded by client cash and what it pays out. Investors have also tracked “cash sorting,” when clients shift idle cash into higher-yielding products, which can change what the firm earns on those balances.

Against that backdrop, traders in Schwab tend to focus on any signal that alters the expected pace of easing in 2026, along with signs of how quickly clients move cash across sweep accounts, bank deposits and money market funds.

Separately, a Form 4 filed with the U.S. Securities and Exchange Commission on Dec. 29 showed Jonathan Beatty, managing director and head of advisor services, exercised options for 2,000 shares and a related trust sold 2,000 shares at a weighted-average price of about $102.01. The filing said the sale was made under a Rule 10b5-1 plan — a pre-arranged program that can automate trades. SEC

Looking ahead, Schwab’s investor relations calendar lists its fourth-quarter results and December monthly activity report for the week of Jan. 19, 2026, with Jan. 21 flagged as the anticipated release date. The company also lists a Winter Business Update on Jan. 21. About Schwab

Those updates will sharpen the focus on net new assets, client cash trends and expense control — key swing factors for 2026 earnings as interest rates turn. Any commentary on net interest income and balance-sheet funding will likely set the tone for how investors price the stock after the holiday lull.

For now, Schwab’s next push is likely to come from the Fed minutes later Tuesday and the market’s reading of how quickly — and how far — policymakers intend to cut rates next year.

Stock Market Today

  • RBC Raises Alphabet (GOOGL) Price Target to $375 Citing AI Advertising Growth
    January 20, 2026, 8:02 AM EST. RBC Capital raised its price target for Alphabet Inc. (NASDAQ: GOOGL) to $375 from $315, maintaining an Outperform rating. The upgrade is driven by momentum in AI-powered advertising, including the rollout of AI Overviews (AIO) ads across platforms like Pmax and Search. RBC highlighted Alphabet's reduction in customer data requirements from 1,000 to 100 users, expanding its total addressable market to more small and medium-sized businesses (SMBs). Additionally, a new connected TV (CTV) product and auction tied to the Olympics are expected to boost ad revenue through inflationary lift. RBC's valuation now reflects a 29.5 times price-to-2027 estimated earnings multiple, up from 28 times based on 2026 estimates. While positive on GOOGL, RBC noted some mixed feedback on AI Mode ads and highlighted challenges with broad keyword matching.
KLA stock dips as China’s 50% domestic chip-tool rule rattles semiconductor equipment names
Previous Story

KLA stock dips as China’s 50% domestic chip-tool rule rattles semiconductor equipment names

Zenas BioPharma stock slides 5% today as biotech shares sag; Phase 3 INDIGO data in focus
Next Story

Zenas BioPharma stock slides 5% today as biotech shares sag; Phase 3 INDIGO data in focus

Go toTop